These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 21317593)

  • 21. The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone.
    Sullivan LE; Botsko M; Cunningham CO; O'Connor PG; Hersh D; Mitty J; Lum PJ; Schottenfeld RS; Fiellin DA;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S54-61. PubMed ID: 21317595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhancing Patient Choice: Using Self-administered Intranasal Naloxone for Novel Rapid Buprenorphine Initiation.
    Randall A; Hull I; Martin SA
    J Addict Med; 2023 Mar-Apr 01; 17(2):237-240. PubMed ID: 36149001
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy.
    Parran TV; Adelman CA; Merkin B; Pagano ME; Defranco R; Ionescu RA; Mace AG
    Drug Alcohol Depend; 2010 Jan; 106(1):56-60. PubMed ID: 19717249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Buprenorphine/naloxone treatment practices in Malaysia: Results of national surveys of physicians and patients.
    Vicknasingam B; Dazali MN; Singh D; Schottenfeld RS; Chawarski MC
    Drug Alcohol Depend; 2015 Jul; 152():164-9. PubMed ID: 25935736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction.
    Worley MJ; Heinzerling KG; Shoptaw S; Ling W
    Addiction; 2017 Jul; 112(7):1202-1209. PubMed ID: 28164407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in pain during buprenorphine maintenance treatment among patients with opioid use disorder and chronic pain.
    Edwards KA; Vowles KE; McHugh RK; Venner KL; Witkiewitz K
    J Consult Clin Psychol; 2022 Apr; 90(4):314-325. PubMed ID: 35007092
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone.
    Bruce RD; Altice FL; Moody DE; Lin SN; Fang WB; Sabo JP; Wruck JM; Piliero PJ; Conner C; Andrews L; Friedland GH
    Drug Alcohol Depend; 2009 Dec; 105(3):234-9. PubMed ID: 19726139
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does the Addition of Naloxone in Buprenorphine/Naloxone Affect Retention in Treatment in Opioid Replacement Therapy?: A Systematic Review and Meta-Analysis.
    Dalton K; Butt N
    J Addict Nurs; 2019; 30(4):254-260. PubMed ID: 31800516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short-term safety of buprenorphine/naloxone in HIV-seronegative opioid-dependent Chinese and Thai drug injectors enrolled in HIV Prevention Trials Network 058.
    Lucas GM; Beauchamp G; Aramrattana A; Shao Y; Liu W; Fu L; Jackson JB; Celentano DD; Richardson P; Metzger D;
    Int J Drug Policy; 2012 Mar; 23(2):162-5. PubMed ID: 21852093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: development and pilot test of a clinical protocol.
    Rosenblum A; Cruciani RA; Strain EC; Cleland CM; Joseph H; Magura S; Marsch LA; McNicholas LF; Savage SR; Sundaram A; Portenoy RK
    J Opioid Manag; 2012; 8(6):369-82. PubMed ID: 23264315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Buprenorphine/Naloxone dose and pain intensity among individuals initiating treatment for opioid use disorder.
    Becker WC; Ganoczy D; Fiellin DA; Bohnert AS
    J Subst Abuse Treat; 2015 Jan; 48(1):128-31. PubMed ID: 25312475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.
    Lee JD; Nunes EV; Novo P; Bachrach K; Bailey GL; Bhatt S; Farkas S; Fishman M; Gauthier P; Hodgkins CC; King J; Lindblad R; Liu D; Matthews AG; May J; Peavy KM; Ross S; Salazar D; Schkolnik P; Shmueli-Blumberg D; Stablein D; Subramaniam G; Rotrosen J
    Lancet; 2018 Jan; 391(10118):309-318. PubMed ID: 29150198
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integration of buprenorphine for substance-abuse treatment by HIV care providers.
    Friedland G; Vlahov D
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S1-2. PubMed ID: 21317588
    [No Abstract]   [Full Text] [Related]  

  • 34. Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids.
    Barocas JA; Morgan JR; Fiellin DA; Schackman BR; Eftekhari Yazdi G; Stein MD; Freedberg KA; Linas BP
    Int J Drug Policy; 2019 Oct; 72():160-168. PubMed ID: 31085063
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic.
    Matson SC; Hobson G; Abdel-Rasoul M; Bonny AE
    J Addict Med; 2014; 8(3):176-82. PubMed ID: 24695018
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Buprenorphine alone or with naloxone: Which is safer?
    Kelty E; Cumming C; Troeung L; Hulse G
    J Psychopharmacol; 2018 Mar; 32(3):344-352. PubMed ID: 29433352
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network.
    Ling W; Amass L; Shoptaw S; Annon JJ; Hillhouse M; Babcock D; Brigham G; Harrer J; Reid M; Muir J; Buchan B; Orr D; Woody G; Krejci J; Ziedonis D;
    Addiction; 2005 Aug; 100(8):1090-100. PubMed ID: 16042639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care.
    Chaudhry AA; Botsko M; Weiss L; Egan JE; Mitty J; Estrada B; Lucas GM; Woodson T; Flanigan TP; Fiellin DA;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S14-21. PubMed ID: 21317589
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methadone and buprenorphine pharmacokinetics and pharmacodynamics when coadministered with fostemsavir to opioid-dependent, human immunodeficiency virus seronegative participants.
    Moore K; Magee M; Sevinsky H; Chang M; Lubin S; Myers E; Ackerman P; Llamoso C
    Br J Clin Pharmacol; 2019 Aug; 85(8):1771-1780. PubMed ID: 30980734
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early buprenorphine-naloxone initiation for opioid use disorder reduces opioid overdose, emergency room visits, and healthcare cost compared to late initiation.
    Sun T; Aroke H; Kogut S; Katenka N; Bratberg J; Buchanan A
    Am J Drug Alcohol Abuse; 2022 Mar; 48(2):217-225. PubMed ID: 34780312
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.